Wave Life Sciences Ltd.
HealthcareNASDAQ:WVE · NASDAQ Global Market
+$0.06 today
Vol 2.24M · Avg 4.87M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-38.8%
avg -91.8%
ROIC
-39.0%
avg -78.7%
ROA
-32.0%
avg -47.5%
Analysis
ROA is currently the strongest return metric at -32.0% versus its period average of -47.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul Bolno | President, Chief Executive Officer & Director | $1.35M | — | 52 | $275,520.00 | 0.14% |
Kyle Moran | Chief Financial Officer & Principal Accounting Officer | $864,681.00 | — | 55 | $134,385.00 | 0.07% |
Chandra Vargeese | Chief Technology Officer | $836,605.00 | — | 65 | $408,246.00 | 0.21% |
Christopher Francis | Senior Vice President of Corporate Development & Head of Emerging Areas | $736,936.00 | — | 48 | $0.00 | <0.01% |
Gregory L. Verdine | Founder & Director | $49,375.00 | — | 67 | $283,197.00 | 0.15% |
Erik Ingelsson | Chief Scientific Officer | — | — | — | $87,864.00 | 0.05% |
Kate Rausch | Head of Investor Relations | — | — | — | — | — |
Sridhar Vaddeboina | Senior Vice President of Chemistry, Manufacturing & Controls | — | — | — | — | — |
Daryn Lewis | Senior Vice President & Head of Human Resources | — | — | — | — | — |
Linda Rockett | Senior Vice President & General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$82.56M
Sells
42
$16.29M
Net Sentiment
+$66.27M
Net buying
Most Active
Francis Chris
11 transactions
1–10 of 48
Analysis
Insiders reported 6 buys worth $82.56M and 42 sells worth $16.29M over the last 12 months. That adds up to net buying of $66.27M. Francis Chris was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +45.8% (13yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +45.8% (13yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Precigen, Inc.
NASDAQ:PGEN
$1.34B
Tourmaline Bio, Inc.
TRML
$1.23B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Upstream Bio, Inc.
UPB
$331.96M
Who manages WVE?
Wave Life Sciences Ltd. (WVE) lists 10 active executives. The top listed executive is Chandra Vargeese, Chief Technology Officer.
Are WVE insiders buying or selling?
Recent insider activity shows net buying of $142.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.